| 1 | Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy显示文摘BACKGROUND Peritoneal metastasis from colorectal cancer(CRC)carries a poor prognosis in most studies.The majority of those studies used either a single-agent or doublet chemotherapy regimen in the first-line setting.AIM To investigate the prognostic significance of peritoneal metastasis in a cohort of patients treated with triplet chemotherapy in the first-line setting.METHODS We retrospectively evaluated progression-free survival(PFS)and overall survival(OS)in 51 patients with metastatic CRC treated in a prospective clinical trial with capecitabine,oxaliplatin,irinotecan,and bevacizumab in the first-line setting according to the presence and absence of peritoneal metastasis.Furthermore,univariate and multivariate analyses for PFS and OS were performed to assess the prognostic significance of peritoneal metastasis at the multivariate level.RESULTS Fifty-one patients were treated with the above triplet therapy.Fifteen had peritoneal metastasis.The patient characteristics of both groups showed a significant difference in the sidedness of the primary tumor(left-sided primary tumor in 60%of the peritoneal group vs 86%in the nonperitoneal group,P=0.03)and the presence of liver metastasis(40%for the peritoneal group vs 75%for the nonperitoneal group,P=0.01).Univariate analysis for PFS showed a statistically significant difference for age less than 65 years(P=0.034),presence of liver metastasis(P=0.046),lung metastasis(P=0.011),and those who underwent metastasectomy(P=0.001).Only liver metastasis and metastasectomy were statistically significant for OS,with P values of 0.001 and 0.002,respectively.Multivariate analysis showed that age(less than 65 years)and metastasectomy were statistically significant for PFS,with P values of 0.002 and 0.001,respectively.On the other hand,the absence of liver metastasis and metastasectomy were statistically significant for OS,with P values of 0.003 and 0.005,respectively.CONCLUSION Peritoneal metastasis in patients with metastatic CRC treated with first-line triple chemotherapy does not carry prognostic significance at univariate and multivariate levels.Confirmatory larger studies are warranted. | Shouki Bazarbashi Abdulrahman Alghabban Mohamed Aseafan Ali H Aljubran Ahmed Alzahrani Tusneem AM Elhassan | 2022 | World Journal of Clinical Cases2022，10，8： | 1 |
| 2 | Calcium supplementation in colorectal cancer prevention:A systematic meta-analysis of adverse events显示文摘Despite the multiple systematic reviews and meta-analyses accumulating evidence on the preventive effect of calcium supplementation for colorectal cancer,most of the associated adverse effects are not systematically analyzed.The aim of the study is evaluating adverse events associated with calcium supplementation for colorectal cancer prevention through a systematic meta-analysis.We searched Medline,PubMed Central,EMBASE(Excerpta Medica database),Scopus,Cochrane Central Register of Controlled Trials,and Web of Science published in English from database inception up to 31 July 2019.In the current systematic meta-analysis,we included human studies(including cohort studies,clinical trials,case-control studies)on supplementation of calcium in patients with or at risk of colorectal cancer.Assessment of the quality of included studies was performed by Jadad score.Information on the patient population,number of enrolled subjects in each group,dose of calcium supplementation,duration of calcium supplementation,and reported adverse events were gathered.The data were pooled for incidence rates for any adverse event during the study period regardless of causality association.We identified 6 studies,comprising 4583 participants that met the inclusion criteria.Meta-analysis on pooled incidence rates for adverse event during study period showed no statistically significant increased risk for cancer(OR=0.92,95%CI:0.70–1.21,P=0.577;I^(2)=0.0%,P=0.731),coronary revascularization(OR=1.12,95%CI:0.79–1.59,P=0.492;I^(2)=0.0%,P=0.957),myocardial infarction(OR=0.81,95%CI:0.34–1.91,P=0.634;I^(2)=67.9%,P=0.047),stroke(OR=0.75,95%CI:0.42–1.33,P=0.332,I^(2)=0.00%,P=0.717),Transient Ischemic Attack(TIA)(OR=1.37,95%CI:0.28–6.51,P=0.692,I^(2)=81.9%,P=0.002),urolithiasis(OR=1.23,95%CI:0.75–2.01,P=0.410;I^(2)=0.0%,P=0.851),fracture(OR=0.98,95%CI:0.70–1.37,P=0.938;I^(2)=37.8%,P=0.152)and death(OR=1.05,95%CI:0.71–1.56,P=0.786,I^(2)=12.2%,P=0.317)in patients receiving calcium supplementation for colorectal cancer prevention compared to control.Based on the results of Egger test,publication bias was not observed among the studies(P=0.262).The current result of the meta-analysis on human studies reporting adverse events associated with calcium supplementation for the prevention of colorectal cancer demonstrated no statistically significant increased risk for the development of adverse events compared to control groups. | XUE MEI LUO SHAHANAVAJ KHAN ABDUL MALIK FAHAD M.ALDAKHEEL ANIS AHMAD CHAUDHARY SHOUKI BAZARBASHI FATEMEH TABATABAIE | 2022 | BIOCELL2022，46，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员